

Gastric atrophy as an important risk factor for gastric cancer development after *Helicobacter pylori* eradication

Tomomitsu Tahara, Noriyuki Horiguchi, Yoshihito Nakagawa, Tomoyuki Shibata, Naoki Ohmiya

Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan

Correspondence to: Tomomitsu Tahara. Department of Gastroenterology, Fujita Health University School of Medicine, 1-98 Dengakugakubo Kutsukake-cho, Toyoake, Aichi 470-1192, Japan. Email: tomomiccyu@yahoo.co.jp.

Comment on: Toyoshima O, Yamaji Y, Yoshida S, *et al.* Endoscopic gastric atrophy is strongly associated with gastric cancer development after *Helicobacter pylori* eradication. Surg Endosc 2016. [Epub ahead of print].

Received: 08 December 2016; Accepted: 30 December 2016; Published: 08 February 2017.

doi: 10.21037/ales.2016.12.12

View this article at: <http://dx.doi.org/10.21037/ales.2016.12.12>

Helicobacter pylori (*H. pylori*) infection plays an important role in gastric cancer development (1). Several studies have demonstrated the possibility of gastric cancer prevention by the *H. pylori* eradication (2,3). However, after successful *H. pylori* eradication, gastric cancers sometimes develop (4,5). Since little has been reported on the risk factors for primary gastric cancer after *H. pylori* eradication, Toyoshima *et al* conducted a retrospective, endoscopy-based, long-term, large-cohort study to clarify the risk factors for gastric cancer following *H. pylori* eradication (6). The author performed 10 years surveillance esophagogastroduodenoscopy of 1,232 cancer-free patients after successful *H. pylori* eradication. Gastric cancer developed in 15 patients (17 lesions) after successful *H. pylori* eradication. The cumulative incidence rates were 1.0% at 2 years, 2.6% at 5 years, and 6.8% at 10 years, respectively. Gastric cancers developed after *H. pylori* eradication were characterized as intestinal type histopathology, within the mucosal layer, and <20 mm in diameter. Multivariate analysis identified higher grade of endoscopic gastric atrophy at *H. pylori* eradication (hazard ratio 1.77; 95% confidence interval, 1.12–2.78; $P=0.01$) as the only independently associated parameter.

It is well known that the pathological state of gastritis, such as severe gastric mucosal atrophy or intestinal metaplasia is closely associated with the risk of gastric cancer among *H. pylori* infected patients (1). Recent studies have also suggested that the severe gastric atrophy at *H. pylori* eradication is associated with increased risk of metachronous gastric cancer (7). Our group has reported that severe gastric atrophy and intestinal metaplasia

remained in the adjacent mucosa of the gastric cancer developed after *H. pylori* eradication (8). The effect of *H. pylori* eradication in preventing gastric cancer can be attributed to the improvement of chronic inflammation or atrophy. However, such effect would be limited in patients with baseline severe atrophic gastritis because gastric atrophy may not improve after *H. pylori* eradication.

The strength of the current study is that the author demonstrated a risk factor for gastric cancer after *H. pylori* eradication among larger cohort of cancer free patients. The author also demonstrated characteristics of gastric cancers developed after *H. pylori* eradication as tiny intra-mucosal cancer with intestinal type histopathology, which is in line with several other studies (4,5). Current result have provided useful information for many endoscopists to perform more appropriate clinical implementation reflecting individual risk for gastric cancer after *H. pylori* eradication.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Annals of Laparoscopic and Endoscopic Surgery*. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/ales.2016.12.12>).

[org/10.21037/ales.2016.12.12](https://doi.org/10.21037/ales.2016.12.12)). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001;345:784-9.
2. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet* 2008;372:392-7.
3. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. *Cancer Epidemiol Biomarkers Prev* 1997;6:639-42.
4. Kamada T, Hata J, Sugiu K, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. *Aliment Pharmacol Ther* 2005;21:1121-6.
5. Horiguchi N, Tahara T, Kawamura T, et al. Distinct Clinic-Pathological Features of Early Differentiated-Type Gastric Cancers after Helicobacter pylori Eradication. *Gastroenterol Res Pract* 2016;2016:8230815.
6. Toyoshima O, Yamaji Y, Yoshida S, et al. Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradication. *Surg Endosc* 2016. [Epub ahead of print].
7. Hanaoka N, Uedo N, Shiotani A, et al. Autofluorescence imaging for predicting development of metachronous gastric cancer after Helicobacter pylori eradication. *J Gastroenterol Hepatol* 2010;25:1844-9.
8. Tahara T, Shibata T, Horiguchi N, et al. A Possible Link between Gastric Mucosal Atrophy and Gastric Cancer after Helicobacter pylori Eradication. *PLoS One* 2016 11:e0163700.

doi: 10.21037/ales.2016.12.12

Cite this article as: Tahara T, Horiguchi N, Nakagawa Y, Shibata T, Ohmiya N. Gastric atrophy as an important risk factor for gastric cancer development after Helicobacter pylori eradication. *Ann Laparosc Endosc Surg* 2017;2:9.